Evidence map›Paper›PMID 37828515›Full record

ArticleJournal of translational medicine2023

Dissecting transcription of the 8q24-MYC locus in prostate cancer recognizes the equilibration between androgen receptor direct and indirect dual-functions.

Ju Guo, Zhao Wei, Tianwei Jia, Liyang Wang, Nuosu Nama, Jiaqian Liang, Xinghua Liao, Xiaming Liu, Yanfei Gao, Xiaoqiang Liu and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 2 countries.

Ju Guo *Department of Urology, The First Affiliated Hospital of Nanchang University, Yongwai Street 17, Nanchang, 330006, China.
Zhao Wei *Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, 250012, Shandong, China.
Tianwei Jia *Department of Clinical Laboratory, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250033, Shandong, China.
Liyang WangHematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, 02215, USA.
Nuosu NamaHematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, 02215, USA.
Jiaqian LiangDepartment of Urology, Wuhan No. 1 Hospital, No. 215 Zhongshan Avenue, Wuhan, China.
Xinghua LiaoInstitute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, No. 947, Heping Avenue, Qingshan District, WuHan, 430081, Hubei, China.
Xiaming LiuDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China.
Yanfei GaoCenter for Medical Epigenetics, School of Basic Medical Sciences, Chongqing Medical University, 1 Yixueyuan Road, Chongqing, 400016, People's Republic of China.
Xiaoqiang LiuDepartment of Urology, The First Affiliated Hospital of Nanchang University, Yongwai Street 17, Nanchang, 330006, China.
Keshan WangHematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, 02215, USA. wks4869@hust.edu.cn.
Bin FuDepartment of Urology, The First Affiliated Hospital of Nanchang University, Yongwai Street 17, Nanchang, 330006, China. urofbin@163.com.
Shaoyong Shawn ChenDepartment of Urology, The First Affiliated Hospital of Nanchang University, Yongwai Street 17, Nanchang, 330006, China. shaoyong_chen@hotmail.com.
Beth Israel Deaconess Medical Center · USHarvard University · USChongqing Medical University · CNFirst Affiliated Hospital of Nanchang University · CNHuazhong University of Science and Technology · CNNanchang University · CNQilu Hospital of Shandong University · CNShanghai Clinical Research Center · CNTongji Hospital · CNWuhan No.1 Hospital · CNWuhan University of Science and Technology · CN

Funding

Androgen Receptor Regulation by PhosphorylationR00CA135592 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CHEN, SHAOYONG · 2011 to 2013
$710k
Androgen Receptor Regulation by PhosphorylationK99CA135592 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CHEN, SHAOYONG · 2008 to 2009
$195k
NCI NIH HHS K99 CA135592NCI NIH HHS R00 CA135592
6 · The paper itself

Abstract

backgroundAndrogen receptor (AR) activation and repression dual-functionality only became known recently and still remains intriguing in prostate cancer (PCa). MYC is a prominent oncogene that functionally entangles with AR signaling in PCa. Further exploration of AR regulatory mechanisms on MYC gene transcription bears clinical and translation significance.

methodsBioinformatics analysis of PCa cell line and clinical RNA-Seq and ChIP-Seq (chromatin immunoprecipitation-sequencing) datasets to anchor interactions of AR and MYC transcriptional networks. ChIP-qPCR and 3C (chromosome conformation capture) analyses to probe MYC distal regulation by AR binding sites (ABSs). CRISPR/Cas9-mediated genome-editing to specify functions of ABS within the 8q24-MYC locus on androgen-mediated MYC transcription. Global FoxA1 and HoxB13 distribution profiling to advance AR transcriptional mechanisms.

resultsHere we recognize AR bi-directional transcription mechanisms by exploiting the prominent 8q24-MYC locus conferring androgen hyper-sensitivity. At ~ 25 Kb downstream of the MYC gene, we identified an undefined ABS, P10. By chromatin analyses, we validated androgen-dependent spatial interaction between P10 and MYC-Promoter (MYC-Pro) and temporal epigenetic repression of these MYC-proximal elements. We next designed a CRISPR/Cas9-mediated double genomic knock-out (KO) strategy to show that P10-KO slightly lessened androgen-elicited MYC transrepression in LNCaP-AR cells. In similar genomic editing assays, androgen-mediated MYC repression became slightly deepened upon KO of P11, an ABS in the PVT1 gene locus highly enriched in AR-binding motifs and peaks. We also investigated multiple ABSs in the established PCAT1 super-enhancer that distally interacts with MYC-Pro for transactivation, with each KO pool consistently shown to relieve androgen-elicited MYC repression. In the end, we systemically assessed androgen effects in the 8q24-MYC locus and along PCa genome to generalize H3K27ac and BRD4 re-distribution from pioneer factors (FoxA1 and HoxB13) to AR sites.

conclusionTogether, we reconciled these observations by unifying AR dual-functions that are mechanistically coupled to and equilibrated by co-factor redistribution.

Indexed as

Prostatic NeoplasmsProto-Oncogene Proteins c-mycReceptors, AndrogenAndrogensBromodomain Containing ProteinsCell Cycle ProteinsCell Line, TumorGene Expression Regulation, NeoplasticHumansMaleNuclear ProteinsTranscription FactorsAndrogensBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsNuclear ProteinsProto-Oncogene Proteins c-mycReceptors, AndrogenTranscription Factors8q24-MYC locusAndrogen receptorAR binding sitesCo-factor redistributionCRIPSR/Cas9 genomic knock-outProstate cancerTranscriptional dual-functions

Identifiers

PMID37828515
PMCPMC10571316
OpenAlexW4387579129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.